TC
REGN icon

Trilogy Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Trilogy Capital’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-15
Closed -$6K – 463
2018
Q3 		$6K Buy
15
+14
+1,400% +$5.33K ﹤0.01% 385
2018
Q2 		$0 Sell
1
-4
-80% -$1.25K ﹤0.01% 613
2018
Q1 		$2K Buy
+5
New +$1.74K ﹤0.01% 402

Other funds holding REGN

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Trilogy Capital's REGN Position: Q4 2018 in Review

Trilogy Capital sold out of Regeneron Pharmaceuticals (REGN) in Q4 2018, closing a stake of 15 shares — an estimated $6K sold.

Trilogy Capital first reported a position in REGN in Q1 2018 and held it in 3 quarters. The position peaked at $6K in Q3 2018. 670 funds tracked by Wall St. Rank hold REGN as of Q4 2018.

  • Trilogy Capital reported no remaining Regeneron Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Trilogy Capital sold 15 Regeneron Pharmaceuticals shares in Q4 2018, an estimated $6K.
  • Trilogy Capital first reported a position in Regeneron Pharmaceuticals in Q1 2018 and held it in 3 quarters.
  • Trilogy Capital's Regeneron Pharmaceuticals position peaked at $6K in Q3 2018.
  • 670 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2018.

Based on Trilogy Capital's 13F filing for Q4 2018, filed 15 Jan 2019.